Table 2.
Aptamers in the Clinical Pipeline
| Aptamer Candidate | Target/Indication | Developer | Clinical phase | Type |
|---|---|---|---|---|
| Macugen (Pegaptanib) | VEGF/AMD | Eyetech(Cedar Knolls, JN, USA) | FDA approved | RNA |
| Edifoligide (E2F decoy) | E2F/CABG surgery | Anesiva (formerly Corgentech, San Francisco, CA, USA) | No better than placebo in Phase III | RNA |
| Avrina (NF-kB decoy) | NF-kB/eczema | Anesvia (formerly Corgentech, San Francisco, CA, USA) | Phase III | ds DNA |
| AS 1411 | Nucleolin/anticancer (AML, renal cell carcinoma) | Antisoma (London, UK) | Phase II | DNA |
| REG1 | FIX/arterial thrombosis | Regado Biosciences (Durham, NC, USA) | Phase II | RNA |
| REG2 | FIX/venous thrombosis | Regado Biosciences (Durham, NC, USA) | Phase I | RNA |
| ARC 1779 (TMA/TTP) | Vwf/TMA, TTP, CEA | Archemix (Cambridge, MA, USA) | Phase II | DNA/RNA |
| ARC 183 | Thrombin/anticoagulation | Archemix (Cambridge, MA, USA) | Phase I completed, not in development | DNA |
| NU172 (ARC2172) | Thrombin/anticoagulation (PCI, CABG) | Nuvelo/Archemix (San Carlos, CA/Cambridge, MA, USA) | Commence a Phase II study | DNA |
| E10030 | PDGF-B/wet AMD | Ophthotech (Princeton, NJ, USA) | Phase I | DNA |
| ARC 1905 | C5/wet and dry AMD | Ophthotech (Princeton, NJ, USA) | Phase I | RNA |